These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 35617333)

  • 1. Resistance training reduced luteinising hormone levels in postmenopausal women in a substudy of a randomised controlled clinical trial: A clue to how resistance training reduced vasomotor symptoms.
    Nilsson S; Henriksson M; Berin E; Engblom D; Holm AS; Hammar M
    PLoS One; 2022; 17(5):e0267613. PubMed ID: 35617333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of resistance training on quality of life in postmenopausal women with vasomotor symptoms.
    Berin E; Hammar M; Lindblom H; Lindh-Åstrand L; Spetz Holm AC
    Climacteric; 2022 Jun; 25(3):264-270. PubMed ID: 34240669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurokinin 3 Receptor Antagonism Reveals Roles for Neurokinin B in the Regulation of Gonadotropin Secretion and Hot Flashes in Postmenopausal Women.
    Skorupskaite K; George JT; Veldhuis JD; Millar RP; Anderson RA
    Neuroendocrinology; 2018; 106(2):148-157. PubMed ID: 28380486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of neurokinin 3 receptor antagonist fezolinetant on hot flash-like symptoms in ovariectomized rats.
    Tahara A; Takamatsu H; Ohtake A; Tanaka-Amino K; Kaku S
    Eur J Pharmacol; 2021 Aug; 905():174207. PubMed ID: 34048742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of kisspeptin/neurokinin B/dynorphin neurons in pathomechanism of vasomotor symptoms in postmenopausal women: from physiology to potential therapeutic applications.
    Szeliga A; Czyzyk A; Podfigurna A; Genazzani AR; Genazzani AD; Meczekalski B
    Gynecol Endocrinol; 2018 Nov; 34(11):913-919. PubMed ID: 29902942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance training for hot flushes in postmenopausal women: A randomised controlled trial.
    Berin E; Hammar M; Lindblom H; Lindh-Åstrand L; Rubér M; Spetz Holm AC
    Maturitas; 2019 Aug; 126():55-60. PubMed ID: 31239119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance training for hot flushes in postmenopausal women: Randomized controlled trial protocol.
    Berin E; Hammar ML; Lindblom H; Lindh-Åstrand L; Spetz Holm AC
    Maturitas; 2016 Mar; 85():96-103. PubMed ID: 26857887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postmenopausal women's experiences of a resistance training intervention against vasomotor symptoms: a qualitative study.
    Berin E; Spetz Holm AC; Hammar M; Lindh-Åstrand L; Berterö C
    BMC Womens Health; 2022 Jul; 22(1):320. PubMed ID: 35907840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lowered progesterone metabolite excretion and a variable LH excretion pattern are associated with vasomotor symptoms but not negative mood in the early perimenopausal transition: Study of Women's Health Across the Nation.
    McConnell DS; Crawford SL; Gee NA; Bromberger JT; Kazlauskaite R; Avis NE; Crandall CJ; Joffe H; Kravitz HM; Derby CA; Gold EB; El Khoudary SR; Harlow S; Greendale GA; Lasley BL
    Maturitas; 2021 May; 147():26-33. PubMed ID: 33832644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of exercise for menopausal symptoms: a randomized controlled trial.
    Sternfeld B; Guthrie KA; Ensrud KE; LaCroix AZ; Larson JC; Dunn AL; Anderson GL; Seguin RA; Carpenter JS; Newton KM; Reed SD; Freeman EW; Cohen LS; Joffe H; Roberts M; Caan BJ
    Menopause; 2014 Apr; 21(4):330-8. PubMed ID: 23899828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying women who share patterns of reproductive hormones, vasomotor symptoms, and sleep maintenance problems across the menopause transition: group-based multi-trajectory modeling in the Study of Women's Health Across the Nation.
    Matthews KA; Chang Y; Brooks MM; Crawford SL; Janssen I; Joffe H; Kravitz HM; Thurston RC; El Khoudary SR
    Menopause; 2020 Oct; 28(2):126-134. PubMed ID: 33038144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms.
    Simon JA; Kaunitz AM; Kroll R; Graham S; Bernick B; Mirkin S
    Menopause; 2019 May; 26(5):506-512. PubMed ID: 30489424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship of longitudinal change in reproductive hormones and vasomotor symptoms during the menopausal transition.
    Randolph JF; Sowers M; Bondarenko I; Gold EB; Greendale GA; Bromberger JT; Brockwell SE; Matthews KA
    J Clin Endocrinol Metab; 2005 Nov; 90(11):6106-12. PubMed ID: 16144949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation and Application of Thresholds to Define Meaningful Change in Vasomotor Symptoms Frequency: Analysis of Pooled SKYLIGHT 1 and 2 Data.
    Morga A; Zimmermann L; Valluri U; Siddiqui E; McLeod L; Bender RH
    Adv Ther; 2024 Jul; 41(7):2845-2858. PubMed ID: 38775925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgens and estrogens in relation to hot flushes during the menopausal transition.
    Øverlie I; Moen MH; Holte A; Finset A
    Maturitas; 2002 Jan; 41(1):69-77. PubMed ID: 11809345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of OASIS 1 and 2: phase 3 clinical trials assessing the efficacy and safety of elinzanetant for the treatment of vasomotor symptoms associated with menopause.
    Pinkerton JV; Simon J; Panay N; Seitz C; Parke S; Caetano C; Mellinger U; Haseli Mashhadi N; Haberland C; Atanackovic G; Holz C; Mao G; Morrison M; Nisius S; Schaefers M; Zuurman L
    Menopause; 2024 Jun; 31(6):522-529. PubMed ID: 38564691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of menopausal vasomotor symptoms with increased bone turnover during the menopausal transition.
    Crandall CJ; Tseng CH; Crawford SL; Thurston RC; Gold EB; Johnston JM; Greendale GA
    J Bone Miner Res; 2011 Apr; 26(4):840-9. PubMed ID: 20878774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. κ Agonists as a novel therapy for menopausal hot flashes.
    Oakley AE; Steiner RA; Chavkin C; Clifton DK; Ferrara LK; Reed SD
    Menopause; 2015 Dec; 22(12):1328-34. PubMed ID: 25988798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 17β-estradiol/progesterone in a single, oral, softgel capsule (TX-001HR) significantly increased the number of vasomotor symptom-free days in the REPLENISH trial.
    Kaunitz AM; Bitner D; Constantine GD; Bernick B; Graham S; Mirkin S
    Menopause; 2020 Dec; 27(12):1382-1387. PubMed ID: 32740481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relation between plasma hormone profiles, symptoms, and response to oestrogen treatment in women approaching the menopause.
    Chakravarti S; Collins WP; Thom MH; Studd JW
    Br Med J; 1979 Apr; 1(6169):983-5. PubMed ID: 219937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.